119 related articles for article (PubMed ID: 23292237)
1. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation.
Ito Y; Miyamoto T; Chong Y; Aoki T; Kato K; Akashi K; Kamimura T
Bone Marrow Transplant; 2013 Jul; 48(7):998-9. PubMed ID: 23292237
[No Abstract] [Full Text] [Related]
2. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma.
Haji S; Kiyasu J; Choi I; Suehiro Y; Toyoda K; Tsuda M; Takamatsu A; Nakashima Y; Miyoshi H; Shiratsuchi M; Yamasaki S; Uike N; Abe Y
Bone Marrow Transplant; 2016 Mar; 51(3):432-4. PubMed ID: 26524267
[No Abstract] [Full Text] [Related]
3. [Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy].
Suwabe T; Shibasaki Y; Kaihatsu A; Katagiri T; Miyakoshi S; Fuse K; Kobayashi H; Ushiki T; Moriyama M; Takizawa J; Narita M; Sone H; Masuko M
Rinsho Ketsueki; 2017; 58(1):32-36. PubMed ID: 28190863
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
5. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
[No Abstract] [Full Text] [Related]
6. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
Motohashi K; Suzuki T; Kishimoto K; Numata A; Nakajima Y; Tachibana T; Ohshima R; Kuwabara H; Tanaka M; Tomita N; Ishigatsubo Y; Fujisawa S
Int J Hematol; 2013 Aug; 98(2):258-60. PubMed ID: 23801427
[TBL] [Abstract][Full Text] [Related]
8. Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies.
Ohyama Y; Kumode T; Eguchi G; Yamaguchi T; Maeda Y
Ann Hematol; 2014 Jan; 93(1):169-71. PubMed ID: 23612772
[No Abstract] [Full Text] [Related]
9. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
11. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.
Fuji S; Utsunomiya A; Inoue Y; Miyagi T; Owatari S; Sawayama Y; Moriuchi Y; Choi I; Shindo T; Yoshida SI; Yamasaki S; Yamaguchi T; Fukuda T
Haematologica; 2018 May; 103(5):e211-e214. PubMed ID: 29371324
[No Abstract] [Full Text] [Related]
13. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
Tobinai K; Takahashi T; Akinaga S
Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
[TBL] [Abstract][Full Text] [Related]
14. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
Zinzani PL; Karlin L; Radford J; Caballero D; Fields P; Chamuleau ME; d'Amore F; Haioun C; Thieblemont C; González-Barca E; García CG; Johnson PW; van Imhoff GW; Ng T; Dwyer K; Morschhauser F
Haematologica; 2016 Oct; 101(10):e407-e410. PubMed ID: 27418646
[No Abstract] [Full Text] [Related]
15. Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab.
Furukawa M; Ikeda K; Ohkawara H; Saito S; Takahashi H; Ueda K; Matsumoto H; Hashimoto Y; Ohto H; Ogawa K; Takeishi Y
Int J Hematol; 2015 Oct; 102(4):498-505. PubMed ID: 25975265
[TBL] [Abstract][Full Text] [Related]
16. Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma.
Kato K; Miyamoto T; Numata A; Nakaike T; Oka H; Yurino A; Kuriyama T; Mori Y; Yamasaki S; Muta T; Takenaka K; Iwasaki H; Teshima T; Akashi K
Int J Hematol; 2013 Mar; 97(3):430-2. PubMed ID: 23397210
[TBL] [Abstract][Full Text] [Related]
17. Production of thymus and activation-regulated chemokine and macrophage-derived chemokine by CCR4+ adult T-cell leukemia cells.
Shimauchi T; Imai S; Hino R; Tokura Y
Clin Cancer Res; 2005 Mar; 11(6):2427-35. PubMed ID: 15788694
[TBL] [Abstract][Full Text] [Related]
18. Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.
Ishitsuka K; Murahashi M; Katsuya H; Mogi A; Masaki M; Kawai C; Goto T; Ishizu M; Ikari Y; Takamatsu Y; Ishibashi H; Nimura S; Takeshita M; Tamura K
Int J Hematol; 2015 Oct; 102(4):493-7. PubMed ID: 25995001
[TBL] [Abstract][Full Text] [Related]
19. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
[No Abstract] [Full Text] [Related]
20. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity.
Kanno K; Honma M; Ishida-Yamamoto A
J Dermatol; 2017 Jun; 44(6):e117-e118. PubMed ID: 28026038
[No Abstract] [Full Text] [Related]
[Next] [New Search]